Načítá se...
Primary resistance to PD-1 blockade mediated by JAK1/2 mutations
Loss of function mutations in JAK1/2 can lead to acquired resistance to anti-programmed death protein 1 (PD-1) therapy. We reasoned they may also be involved in primary resistance to anti-PD-1 therapy. JAK1/2 inactivating mutations were noted in tumor biopsies of 1 of 23 patients with melanoma and i...
Uloženo v:
| Vydáno v: | Cancer Discov |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5296316/ https://ncbi.nlm.nih.gov/pubmed/27903500 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-16-1223 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|